Targeting Ras in HCC | Nature Reviews Gastroenterology & Hepatology

Access through your institution Buy or subscribe Newell, P. _ et al_. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin _in

vivo_. _J. Hepatol._ 51, 725–733 (2009). Only about 30% of patients with hepatocellular carcinoma (HCC) are eligible to receive curative therapies and, even in these patients, recurrence

rates are still high. Consequently, new therapeutic strategies are required. Pippa Newell and colleagues found that molecular alterations of the Ras pathway are common in HCC and that the

multikinase inhibitor sorafenib, given alone or in combination with the mTOR inhibitor rapamycin, had antineoplastic effects in experimental models. This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support Authors * Ezzie Hutchinson View author publications You can also search for this

author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hutchinson, E. Targeting Ras in HCC. _Nat Rev Gastroenterol Hepatol_ 6,

689 (2009). https://doi.org/10.1038/nrgastro.2009.191 Download citation * Issue Date: December 2009 * DOI: https://doi.org/10.1038/nrgastro.2009.191 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative